Expression of CD116, CD123 and CD45RA on CD4+CD56+ tumor cells
Patient no. . | CD116 . | CD123 . | CD45 RA . |
---|---|---|---|
2 | W | + | + |
3 | W | + | + |
6 | − | + | + |
7 | − | + | + |
8 | − | + | + |
10 | − | + | + |
113-150 | W | + | + |
133-150 | − | + | ND |
14 | W | + | + |
16 | W | + | + |
18 | − | + | + |
21 | W | + | + |
223-150 | − | + | + |
23 | W | + | + |
Frequencies | 7W/14 | 14/14 | 13/13 |
50% | 100% | 100% |
Patient no. . | CD116 . | CD123 . | CD45 RA . |
---|---|---|---|
2 | W | + | + |
3 | W | + | + |
6 | − | + | + |
7 | − | + | + |
8 | − | + | + |
10 | − | + | + |
113-150 | W | + | + |
133-150 | − | + | ND |
14 | W | + | + |
16 | W | + | + |
18 | − | + | + |
21 | W | + | + |
223-150 | − | + | + |
23 | W | + | + |
Frequencies | 7W/14 | 14/14 | 13/13 |
50% | 100% | 100% |
W indicates weak.
Immunophenotypic data obtained during secondary medullary dissemination.